Shares of Pfizer Inc. (NYSE:PFE) have been assigned an average rating of “Hold” from the twenty-six analysts that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and nine have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $43.25.

Several research firms recently commented on PFE. Cantor Fitzgerald set a $45.00 target price on Pfizer and gave the company a “buy” rating in a research report on Monday, August 27th. Deutsche Bank set a $45.00 price target on Pfizer and gave the company a “buy” rating in a research report on Tuesday, August 21st. JPMorgan Chase & Co. reissued a “buy” rating and set a $42.00 price objective on shares of Pfizer in a research note on Thursday, August 23rd. Credit Suisse Group set a $40.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, August 28th. Finally, Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th.

In related news, major shareholder Pfizer Inc bought 55,556 shares of the business’s stock in a transaction on Monday, October 15th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the transaction, the insider now directly owns 21,976,484 shares of the company’s stock, valued at approximately $395,576,712. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.06% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. 10 15 Associates Inc. grew its holdings in shares of Pfizer by 5.5% during the first quarter. 10 15 Associates Inc. now owns 348,102 shares of the biopharmaceutical company’s stock valued at $12,354,000 after buying an additional 18,087 shares during the last quarter. Beaumont Financial Partners LLC increased its holdings in Pfizer by 62.3% during the 1st quarter. Beaumont Financial Partners LLC now owns 19,582 shares of the biopharmaceutical company’s stock worth $695,000 after acquiring an additional 7,519 shares during the period. Dimensional Fund Advisors LP increased its holdings in Pfizer by 11.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 47,174,487 shares of the biopharmaceutical company’s stock worth $1,674,223,000 after acquiring an additional 4,998,981 shares during the period. Wsfs Capital Management LLC bought a new stake in Pfizer during the 1st quarter worth approximately $439,000. Finally, Eldridge Investment Advisors Inc. purchased a new position in Pfizer in the 1st quarter worth approximately $243,000. 69.42% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE PFE traded down $0.16 on Friday, hitting $44.98. The company had a trading volume of 30,409,228 shares, compared to its average volume of 22,249,297. Pfizer has a 12-month low of $33.20 and a 12-month high of $46.47. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.15. The company has a market capitalization of $268.71 billion, a price-to-earnings ratio of 16.97, a PEG ratio of 2.25 and a beta of 0.88.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.03. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The company had revenue of $13.30 billion for the quarter, compared to the consensus estimate of $13.53 billion. During the same quarter last year, the business posted $0.67 EPS. Pfizer’s quarterly revenue was up 1.0% compared to the same quarter last year. Research analysts expect that Pfizer will post 3 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Monday, December 3rd. Investors of record on Friday, November 9th were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, November 8th. This represents a $1.36 annualized dividend and a dividend yield of 3.02%. Pfizer’s dividend payout ratio is 51.32%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

See Also: How Important is Technical Analysis of Stocks

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.